An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis
Phase of Trial: Phase II
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs Etrasimod (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Arena Pharmaceuticals
- 14 May 2019 Status changed from recruiting to discontinued.
- 13 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 13 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.